Сторінка 1 від 46 результати
FIELD OF THE INVENTION
The present invention relates generally to inhibition of monoamine oxidases (MAOs) and their inhibitors (MAOIs) as strategies to treat cancer, particularly prostate cancer. This invention also relates to imaging, screening, diagnostics, and therapeutic methods of cancer. In
INTRODUCTION
1. Technical Field
The field of this invention is diagnosis of diseased states and therapeutic treatments of diseased states, using NADH oxidase as the target.
2. Background
Enzymatic transfer of electrons from reduced pyridine nucleotide (NADH) to molecular oxygen in the absence of
TECHNICAL FIELD
Both embodiments of the invention herein are directed at the use of melphalan as an anti-tumor agent.
BACKGROUND OF THE INVENTION
Melphalan, (4-[bis(2-chloroethyl)amino]-L-phenylalanine), is a nitrogen mustard that is useful as a chemotherapeutic agent. Goodman and Gilman's The
TECHNICAL FIELD
This invention is directed at the use of melphalan as an anti-tumor agent.
BACKGROUND OF THE INVENTION
Melphalan, (4-[bis(2-chloroethyl)amino]-L-phenylalanine), is a nitrogen mustard that is useful as a chemotherapeutic agent against many tumors. With cells grown in culture, it is
BACKGROUND
Breast cancer is a significant health concern in the United States, representing the second leading cause of cancer death in women. The lethality of breast cancers reflects their acquisition of invasive and metastatic phenotypes, events that account for nearly 90% of the mortality
BACKGROUND OF THE INVENTION
This invention relates to biochemistry and more particularly to an enzymatic preparation for the control of tumor growth and immune diseases, and a process of inserting said preparation into mammals.
Ample evidence has shown that the combination of certain peroxidases
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a .sctn. 371 national stage of PCT International Application No. PCT/AU2017/000040, filed Feb. 10, 2017, claiming priority of Australian Patent Applications Nos. 2016902593, filed Jul. 1, 2016, and 2016900478, filed Feb. 12, 2016, the
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a .sctn. 371 national stage of PCT International Application No. PCT/AU2017/000039, filed Feb. 10, 2017, claiming priority of Australian Patent Applications Nos. 2016902593, filed Jul. 1, 2016 and 2016900478, filed Feb. 12, 2016, the
INTRODUCTION
Skin neoplasms may occur in many different parts of the body. Symptoms associated with skin neoplasms include, e.g., changes in the color and/or appearance of the skin, such as the formation of a colored patch of skin, the formation of a new growth, and/or the formation of a sore or
One aspect of this invention relates to the photodynamic treatment of mammalian tumor cells, as in the photodynamic treatment of cancer.
It is by now well known to supply hematoporphyrin derivative or a mixture of porphyrins derived therefrom (e.g. Photofrin II.RTM.) to mammalian tumor cells and
One aspect of this invention relates to the photodynamic treatment of mammalian tumor cells, as in the photodynamic treatment of cancer.
It is by now well known to supply hematoporphyrin derivative or a mixture of porphyrins derived therefrom (e.g. Photofrin II,) to mammalian tumor cells and then
DESCRIPTION OF THE INVENTION
1. Technical Field of the Invention
This invention relates to a screening test for large intestinal cancer by detecting the presence of the disaccharide .beta.-D-Gal-(1->>3)-D-GalNAc in large intestinal mucus.
2. Background Art
Cancer of the colon, cecum, and
FIELD OF THE INVENTION
The present invention relates generally to inhibition of monoamine oxidases (MAOs) and their inhibitors (MAOIs) in the treatment of brain cancer.
BACKGROUND OF THE INVENTION
Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumors, with a median
FIELD OF THE INVENTION
The present invention relates generally to inhibition of monoamine oxidases (MAOs) and their inhibitors (MAOIs) in the treatment of brain cancer.
BACKGROUND OF THE INVENTION
Glioblastoma multiforme (GBM) is the most malignant form of primary brain tumors, with a median
FIELD OF THE INVENTION
This invention has its application in the Medical and Veterinary Oncology, for detection and tracking of malign tumours, particularly inscribed in the field of Biotechnology. From a conceptual point of view, the catalytic subunit .beta. of the mitochondrial complex of the